Picture of Verici Dx logo

VRCI Verici Dx Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m+2.3%
3m+0.41%
6m+3.74%
1yr+45.79%
Volume Change (%)
10d/3m-76.53%
Price vs... (%)
52w High-48.68%
50d MA+0.06%
200d MA+2.61%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value4.46
Price to Tang. Book6.41
Price to Free Cashflown/a
Price to Sales1,568.35
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-169.87%
Return on Equity-92.28%
Operating Margin-59794.74%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Verici Dx EPS forecast chart

Profile Summary

Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    June 30th, 2023
    Incorporated
    April 22nd, 2020
    Public Since
    November 3rd, 2020
    No. of Employees
    14
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    gb flag iconLondon Stock Exchange
    Shares in Issue
    242,541,467

    VRCI Share Price Performance

    Latest News for VRCI

    Upcoming Events for VRCI

    Full Year 2023 Verici Dx Plc Earnings Release

    Verici DX PLC Annual Shareholders Meeting

    Half Year 2024 Verici Dx Plc Earnings Release

    Similar to VRCI

    Picture of Abingdon Health logo

    Abingdon Health

    gb flag iconLondon Stock Exchange

    Picture of Advanced Medical Solutions logo

    Advanced Medical Solutions

    gb flag iconLondon Stock Exchange

    Picture of Advanced Oncotherapy logo

    Advanced Oncotherapy

    gb flag iconLondon Stock Exchange

    Picture of Angle logo

    Angle

    gb flag iconLondon Stock Exchange

    Picture of Aptamer logo

    Aptamer

    gb flag iconLondon Stock Exchange

    FAQ